Committee

EQS-News: NEON EQUITY AG establishes high-caliber Impact Advisory Board with renowned ESG experts

Retrieved on: 
Wednesday, March 13, 2024

Frankfurt am Main, February 29, 2024 - NEON EQUITY AG (NEON EQUITY ISIN: DE000A3DW408), a founder-led investor and growth enabler, introduces its newly established Impact Advisory Board.

Key Points: 
  • Frankfurt am Main, February 29, 2024 - NEON EQUITY AG (NEON EQUITY ISIN: DE000A3DW408), a founder-led investor and growth enabler, introduces its newly established Impact Advisory Board.
  • One of the aims of the Board is to create new investment opportunities for NEON EQUITY in the field of impact investing.
  • I am delighted to have gained four such renowned ESG experts as initiators, advisors and sparring partners for NEON EQUITY.
  • NEON EQUITY itself will of course also benefit from the in-depth expertise of each individual member of our Impact Advisory Board.

Polymetal International plc: Proposed divestment of Polymetal Group’s Russian business and notice of General Meeting

Retrieved on: 
Wednesday, March 13, 2024

Polymetal International plc (“Polymetal”, the “Company” or the “Group”) announces today that it has entered into contracts for the divestment of its Russian business for an effective total consideration of approximately US$3.69 billion (the “Transaction”).

Key Points: 
  • Polymetal International plc (“Polymetal”, the “Company” or the “Group”) announces today that it has entered into contracts for the divestment of its Russian business for an effective total consideration of approximately US$3.69 billion (the “Transaction”).
  • A quick, transparent, and sanctions-compliant exit under the terms of the proposed Transaction serves the interests of all stakeholders.
  • The completion of the divestment will allow the Group to de-risk the Company’s business, deliver stable cash flows and pursue new investment opportunities.
  • The Transaction values the Russian business at approximately US$3.69 billion [1] including third-party debt and intra-group arrangements detailed in the Circular.

SEC Investor Advisory Committee to Discuss Proposals to Improve Equity Market Structure and Examine the Use of Materiality as a Disclosure Standard

Retrieved on: 
Thursday, February 29, 2024

Washington, D.C.--(Newsfile Corp. - February 29, 2024) - The Securities and Exchange Commission’s Investor Advisory Committee will hold a public meeting on March 7 at 10 a.m.

Key Points: 
  • Washington, D.C.--(Newsfile Corp. - February 29, 2024) - The Securities and Exchange Commission’s Investor Advisory Committee will hold a public meeting on March 7 at 10 a.m.
  • The committee will host two panels:
    Discussing the U.S. Securities and Exchange Commission’s Proposals to Improve Equity Market Structure; and
    Examining the Use of Materiality as a Disclosure Standard – Can the Definition be Improved to Better Serve Investors?
  • The Investor Advisory Committee, which focuses on investor-related interests, advises the Commission on regulatory priorities and various initiatives to help protect investors and promote the integrity of the U.S. securities markets.
  • Established by the Dodd-Frank Act , the Committee is authorized by Congress to submit findings and recommendations to the Commission.

First Phosphate Project Receives Letter of Support from Mario Simard, Canadian Parliamentary Deputy for the Riding of Jonquière, Québec

Retrieved on: 
Thursday, February 22, 2024

Mario Simard, Member of Parliament (BQ) for the Riding of Jonquière, Québec.

Key Points: 
  • Mario Simard, Member of Parliament (BQ) for the Riding of Jonquière, Québec.
  • Mr. Simard, first elected to Canadian parliament in 2019, is the vice-chair of the Standing Committee on Natural Resources and is the critic for natural resources for the Bloc Québécois.
  • They provide the electric vehicle sector with environmentally-friendly batteries through their production process powered by our clean Quebec hydroelectric grid."
  • "This is why, as MP for the federal riding of Jonquière, I support a project as important as that of First Phosphate for the development of LFP battery in the Saguenay-Lac-Saint-Jean region."

Travere Therapeutics Submits Supplemental New Drug Application to the U.S. Food and Drug Administration Seeking Full Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy (IgAN)

Retrieved on: 
Monday, March 11, 2024

The sNDA is based on 2-year confirmatory results from the Phase 3 PROTECT Study, the only head-to-head study in IgAN versus an active comparator.

Key Points: 
  • The sNDA is based on 2-year confirmatory results from the Phase 3 PROTECT Study, the only head-to-head study in IgAN versus an active comparator.
  • “Since being introduced under accelerated approval, FILSPARI has positively impacted the lives of many people living with IgAN.
  • “FILSPARI is at the forefront of emerging new treatment options providing hope for a delay in kidney transplant or dialysis.
  • The FDA has 60 days from the receipt of the application to determine whether to accept it for review.

R1 RCM Forms Special Committee to Evaluate Strategic Alternatives

Retrieved on: 
Monday, March 11, 2024

MURRAY, Utah, March 11, 2024 (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ: RCM) (“R1” or the “Company”), a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers, today announced the formation of a special committee comprised solely of independent directors (the “Special Committee”) to evaluate strategic alternatives in response to the Schedule 13D/A filed by New Mountain Capital, L.L.C.

Key Points: 
  • MURRAY, Utah, March 11, 2024 (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ: RCM) (“R1” or the “Company”), a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers, today announced the formation of a special committee comprised solely of independent directors (the “Special Committee”) to evaluate strategic alternatives in response to the Schedule 13D/A filed by New Mountain Capital, L.L.C.
  • Consistent with its fiduciary duties, and in consultation with its independent advisors, the Special Committee will carefully review the communications from New Mountain Capital and evaluate strategic alternatives to determine the course of action that it believes is in the best interests of R1 and its stockholders.
  • R1 remains focused on providing clients with world-class revenue cycle solutions to help providers improve their financial performance and deliver an exceptional patient experience.
  • No assurances can be given regarding the outcome or timing of the Special Committee’s review process.

Samsung Bioepis Presents Two Abstracts for Its Immunology Portfolio at the 2024 American Academy of Dermatology (AAD) Annual Meeting

Retrieved on: 
Saturday, March 9, 2024

“We are excited to present new clinical data for our immunology portfolio at AAD Annual Meeting.

Key Points: 
  • “We are excited to present new clinical data for our immunology portfolio at AAD Annual Meeting.
  • The high-concentration (40 mg/0.4 mL) formulation of prefilled syringe and prefilled autoinjector of HADLIMA was approved in August 2022.
  • The study showed that efficacy, safety, and immunogenicity between the three arms were comparable up to Week 52.
  • Details of the Samsung Bioepis’ abstracts are as follows:
    Clinical Similarity of SB17 (Proposed Ustekinumab Biosimilar) to Reference Ustekinumab in Patients with Moderate to Severe Plaque Psoriasis: Randomized, Double-blind, Phase III, 52-Week Results

AAFA Statement on Asthma Inhaler Price Caps

Retrieved on: 
Friday, March 8, 2024

Boehringer Ingelheim announced it will cap out-of-pocket costs of its COPD and asthma inhaler portfolio at $35 per month for patients who have commercial insurance or no insurance.

Key Points: 
  • Boehringer Ingelheim announced it will cap out-of-pocket costs of its COPD and asthma inhaler portfolio at $35 per month for patients who have commercial insurance or no insurance.
  • “The announced price cap from Boehringer Ingelheim is a step toward improving access to essential asthma medicine and demonstrates that the voice of the asthma patient community is being heard,” states Kenneth Mendez, president and CEO of AAFA.
  • “AAFA will continue to advocate that all stakeholders in the drug pricing ecosystem take steps to improve affordability and access for life-saving medicines.”
    Last fall, AAFA shared patient stories and its Asthma Disparities in America report with the Senate Health, Education, Labor, and Pensions (HELP) Committee which then launched an investigation into the high price of asthma inhalers early this year.
  • In addition to pharmaceutical manufacturers, pharmacy benefit managers, insurance companies, employers, and federal policies all affect the final price paid for medicines.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Calavo Growers, Inc. - CVGW

Retrieved on: 
Thursday, March 7, 2024

NEW YORK, March 07, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Calavo Growers, Inc. (“Calavo” or the “Company”) (NASDAQ: CVGW).

Key Points: 
  • NEW YORK, March 07, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Calavo Growers, Inc. (“Calavo” or the “Company”) (NASDAQ: CVGW).
  • The investigation concerns whether Calavo and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.
  • The Firm has recovered billions of dollars in damages awards on behalf of class members.

Whitestone REIT Board of Trustees Rejects Nomination of Two Erez Candidates

Retrieved on: 
Thursday, March 7, 2024

HOUSTON, March 07, 2024 (GLOBE NEWSWIRE) -- Whitestone REIT received notice that Erez Asset Management, LLC ("Erez") has nominated two candidates to stand for election to the Board of Trustees of Whitestone REIT (the “Whitestone Board”) at the 2024 annual meeting.

Key Points: 
  • HOUSTON, March 07, 2024 (GLOBE NEWSWIRE) -- Whitestone REIT received notice that Erez Asset Management, LLC ("Erez") has nominated two candidates to stand for election to the Board of Trustees of Whitestone REIT (the “Whitestone Board”) at the 2024 annual meeting.
  • The Whitestone REIT Nominating and Governance Committee (“the Committee”) has conducted a comprehensive review and evaluation of Erez candidates Bruce Schanzer and Catherine Clark.
  • Pursuant to the recommendation of the Committee, the Whitestone Board will not nominate either candidate.
  • The Whitestone Board has strong retail REIT experience, as well as experience across a full range of disciplines that enhance their oversight capabilities.